Company intelligence / Profile preview

Lyndra Therapeutics

Watertown, Massachusetts, United Stateslyndra.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Lyndra’s lead candidate—oral weekly risperidone—achieved a phase III efficacy win in adult patients with schizophrenia and schizoaffective disorder as of January 2024. The study was stopped early due to positive interim results showing comparable efficacy to daily Risperdal. A phase III safety trial will begin in the first half of 2025. The LYNX platform has demonstrated clinical proof-of-concept across five therapeutic areas using over twenty-five APIs.

Therapeutic areas: Infectious DiseasesPsychiatryWomen's Health
Modalities: Small molecules (oral formulations)Potential for peptides and other APIs (platform supports multiple modalities)
Industry: Biotech

Drug pipeline

11 assets

levomethadone

Approved

10 more assets in the full pipeline.

Request access →

Partnerships

Thermo Fisher Scientific – strategic collaboration for research & commercial manufacturing services leveraging Thermo Fisher’s CDMO/CRO capabilities including commercial-scale production of LYNX-based products.

Beyond the preview

Go deeper on Lyndra Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lyndra Therapeutics.

Explore the full profile